As leaders in cardiology, the physicians at Carient are committed to continuing their education and growing their understanding of the best practices and treatments. Often, this new knowledge comes about through clinical research, which is why our team at Carient is dedicated to conducting and participating in research protocols. The insights revealed through clinical research will enable our patients to obtain the newest treatments before they are available to the general public. Carient is one of the few sites in Northern Virginia that participates in large cardiovascular clinical trials that are otherwise only available to major academic centers.
Carient’s physicians are honored to participate in vital and impactful clinical research in the field of cardiology. This research ultimately leads to new advancements in the care we provide our patients. We have been selected to participate in many elite Cardiovascular Research Studies of new interventional devices and treatment modalities.
The Clinical Research Institute at Carient was established in 2010 under the supervision of Dr. Hamid Taheri. We have been selected to participate in many elite Cardiovascular Research Studies of new interventional devices and treatment modalities.
We are currently accepting new patients into the following studies:
VICTOR is a study to evaluate the effect of a new medication to treat adults with Congestive Heart Failure. Vericiguat was approved by the FDA in January 2021. Participation is up to 3.5 years.
EMPACT MI is designed to evaluate the effect of empagliflozin on hospitalization for heart failure and mortality in patients with a recent heart attack. Participation is up to 2 years.
HERMES is a study to evaluate the effect of a new medication, added to standard of care, in reducing the risk of cardiovascular death and Heart Failure events in patients with mildly reduced EF (ejection fraction) and inflammation. Participation is up to 3 years.
OCEANIC AF is a study comparing Apixaban to a new medication for the prevention of stroke in patients with atrial fibrillation. Participation is up to 3 years.
LILAC is a study to evaluate the effectiveness of a new medication to treat high risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation. Participation is up to 2 years.
ORION4 is a study designed to determine if a new cholesterol lowering injectable safely lowers the risk of heart attack or stroke in patients who have a history of blocked arteries. Inclisiran was approved by the FDA in January 2022. Participation is up to 5 years.
OCEAN(a) is a study to assess the impact of Olpasiran on major Cardiovascular events in patient with elevated Lipoprotein(a). Participation is up to 5 years.
PREVAIL is a study to evaluate the effect of a new cholesterol medication for patients who are not adequately controlled despite maximally tolerated lipid modifying therapies. Participation is up to 3 years.
ESSENCE is a study designed to evaluate the effect of a new medication on fasting Triglyceride levels in patients with Cardiovascular Disease and Hypertriglyceridemia. Participation is 1 year.
Please contact the Research Department via text or phone at 571.581.1771 for more information or if you are interested in participating in a study. Your provider can also speak to you more about being a candidate for a research study during your office visit. To be directed to ClinicalTrials.gov for a detailed description about each study, please click on the study title.
Additional research can be found by visiting clinicaltrials.gov